Indolent Lymphoma - Pipeline Review, H2 2016

Date: August 10, 2016
Pages: 213
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: IB1EA1C66F1EN
Leaflet:

Download PDF Leaflet

Indolent Lymphoma - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Indolent Lymphoma - Pipeline Review, H2 2016’, provides an overview of the Indolent Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Indolent Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Indolent Lymphoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma
  • The report reviews pipeline therapeutics for Indolent Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Indolent Lymphoma therapeutics and enlists all their major and minor projects
  • The report assesses Indolent Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Indolent Lymphoma
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Indolent Lymphoma Overview
Therapeutics Development
Pipeline Products for Indolent Lymphoma - Overview
Indolent Lymphoma - Therapeutics under Development by Companies
Indolent Lymphoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Indolent Lymphoma - Products under Development by Companies
Indolent Lymphoma - Companies Involved in Therapeutics Development
AbbVie Inc
Affimed GmbH
Altor BioScience Corporation
Amgen Inc.
Astellas Pharma Inc.
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Juno Therapeutics Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals Inc
MorphoSys AG
Novartis AG
Seattle Genetics, Inc.
Trillium Therapeutics Inc.
Indolent Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AFM-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALT-803 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bendamustine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-836826 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blinatumomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTH-1677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
copanlisib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DI-B4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
duvelisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entospletinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibrutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-40093 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-50465 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inebilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inebilizumab + MEDI-0680 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itacitinib adipate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JCAR-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JCAR-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JCAR-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenalidomide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3023414 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-208 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obinutuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ofatumumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEA-CD40 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-659 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTI-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
venetoclax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Indolent Lymphoma - Dormant Projects
Indolent Lymphoma - Discontinued Products
Indolent Lymphoma - Product Development Milestones
Featured News & Press Releases
Jun 04, 2016: Juno Therapeutics To present Data on JCAR017 at the 52nd Annual Meeting of the American Society
Nov 30, 2015: New Data from Bayer’s Portfolio in Oncology to be Presented at ASH 2015
Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting
Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG
Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH
Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting
Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH)
Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Indolent Lymphoma, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Indolent Lymphoma - Pipeline by AbbVie Inc, H2 2016
Indolent Lymphoma - Pipeline by Affimed GmbH, H2 2016
Indolent Lymphoma - Pipeline by Altor BioScience Corporation, H2 2016
Indolent Lymphoma - Pipeline by Amgen Inc., H2 2016
Indolent Lymphoma - Pipeline by Astellas Pharma Inc., H2 2016
Indolent Lymphoma - Pipeline by Bayer AG, H2 2016
Indolent Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Indolent Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
Indolent Lymphoma - Pipeline by Celgene Corporation, H2 2016
Indolent Lymphoma - Pipeline by Eli Lilly and Company, H2 2016
Indolent Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Indolent Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2016
Indolent Lymphoma - Pipeline by Incyte Corporation, H2 2016
Indolent Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016
Indolent Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2016
Indolent Lymphoma - Pipeline by MedImmune, LLC, H2 2016
Indolent Lymphoma - Pipeline by Merck & Co., Inc., H2 2016
Indolent Lymphoma - Pipeline by Merck KGaA, H2 2016
Indolent Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Indolent Lymphoma - Pipeline by MorphoSys AG, H2 2016
Indolent Lymphoma - Pipeline by Novartis AG, H2 2016
Indolent Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016
Indolent Lymphoma - Pipeline by Trillium Therapeutics Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Indolent Lymphoma - Dormant Projects, H2 2016
Indolent Lymphoma - Dormant Projects (Contd.1), H2 2016
Indolent Lymphoma - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Indolent Lymphoma, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

AbbVie Inc
Affimed GmbH
Altor BioScience Corporation
Amgen Inc.
Astellas Pharma Inc.
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Juno Therapeutics Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals Inc
MorphoSys AG
Novartis AG
Seattle Genetics, Inc.
Trillium Therapeutics Inc.
Skip to top


T-Cell Lymphomas - Pipeline Review, H2 2014 US$ 1,500.00 Oct, 2014 · 143 pages

Ask Your Question

Indolent Lymphoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: